ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer.

MLA

Ge, Li-Ping, et al. “ZNF689 Deficiency Promotes Intratumor Heterogeneity and Immunotherapy Resistance in Triple-Negative Breast Cancer.” Cell Research, vol. 34, no. 1, Jan. 2024, pp. 58–75. EBSCOhost, https://doi.org/10.1038/s41422-023-00909-w.

APA

Ge, L.-P., Jin, X., Ma, D., Wang, Z.-Y., Liu, C.-L., Zhou, C.-Z., Zhao, S., Yu, T.-J., Liu, X.-Y., Di, G.-H., Shao, Z.-M., & Jiang, Y.-Z. (2024). ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell Research, 34(1), 58–75. https://doi.org/10.1038/s41422-023-00909-w

Chicago

Ge, Li-Ping, Xi Jin, Ding Ma, Zi-Yu Wang, Cheng-Lin Liu, Chao-Zheng Zhou, Shen Zhao, et al. 2024. “ZNF689 Deficiency Promotes Intratumor Heterogeneity and Immunotherapy Resistance in Triple-Negative Breast Cancer.” Cell Research 34 (1): 58–75. doi:10.1038/s41422-023-00909-w.